EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elevated plasma neurofilament light and glial fibrillary acidic protein in epilepsy versus nonepileptic seizures and nonepileptic disorders

Hannah Dobson iD, Said Al Maawali iD, Charles Malpas iD, Alexander F Santillo, Matthew Kang, Marian Todaro, Rosie Watson, Nawaf Yassi, Kaj Blennow, Henrik Zetterberg, Emma Foster iD, Andrew Neal iD und 4 weitere

Epilepsia · 2024

DOI: 10.1111/epi.18065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2024. Verfasst von Hannah Dobson und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Alfred Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Glial Fibrillary Acidic Protein, Neurofilament Proteins, Epilepsy, Seizures. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MACH MRFF RART 2.2, National Health & Medical Research Council, MRFF Practitioner Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Research suggests that recurrent seizures may lead to neuronal injury. Neurofilament light chain protein (NfL) and glial fibrillary acidic protein (GFAP) levels increase in cerebrospinal fluid and blood in response to neuroaxonal damage, and they have been hypothesized as potential biomarkers for epilepsy. We examined plasma NfL and GFAP levels and their diagnostic utility in differentiating patients with epilepsy from those with psychogenic nonepileptic seizures (PNES) and other nonepileptic disorders.

Methods

We recruited consecutive adults admitted for video‐electroencephalographic monitoring and formal neuropsychiatric assessment. NfL and GFAP levels were quantified and compared between different patient groups and an age‐matched reference cohort ( n = 1926) and correlated with clinical variables in patients with epilepsy.

Results

A total of 138 patients were included, of whom 104 were diagnosed with epilepsy, 22 with PNES, and 12 with other conditions. Plasma NfL and GFAP levels were elevated in patients with epilepsy compared to PNES, adjusted for age and sex (NfL p = .04, GFAP p = .04). A high proportion of patients with epilepsy (20%) had NfL levels above the 95th age‐matched percentile compared to the reference cohort (5%). NfL levels above the 95th percentile of the reference cohort had a 95% positive predictive value for epilepsy. Patients with epilepsy who had NfL levels above the 95th percentile were younger than those with lower levels (37.5 vs. 43.8 years, p = .03). Significance An elevated NfL or GFAP level in an individual patient may support an underlying epilepsy diagnosis, particularly in younger adults, and cautions against a diagnosis of PNES alone. Further examination of the association between NfL and GFAP levels and specific epilepsy subtypes or seizure characteristics may provide valuable insights into disease heterogeneity and contribute to the refinement of diagnosis, understanding pathophysiological mechanisms, and formulating treatment approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glial Fibrillary Acidic ProteinNeurofilament ProteinsEpilepsySeizuresBiomarkersHumansFemaleMaleAdultMiddle AgedElectroencephalographyYoung AdultAgedDiagnosis, Differential

Stichwörter der Autor:innen

biomarkerepilepsyglial fibrillary acidic proteinneurofilament light chainnonepileptic seizures

Substanzen

Glial Fibrillary Acidic ProteinNeurofilament Proteinsneurofilament protein LGFAP protein, humanBiomarkers

Autor:innen und Institutionen

  • Department of Psychiatry, Alfred Health, Melbourne, Victoria, Australia.
  • Neuropsychiatry Centre, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
  • Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia.
  • Clinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund/Malmö, Sweden.

ORCID-Profile: Hannah Dobson, Said Al Maawali, Charles Malpas, Emma Foster, Andrew Neal, Dhamidhu Eratne, Patrick Kwan

Förderung

  • MACH MRFF RART 2.2
  • National Health & Medical Research Council
  • MRFF Practitioner Fellowship
  • National Health and Medical Research Council

Zitieren

APA

Dobson, H., Al Maawali, S., Malpas, C., Santillo, A. F., Kang, M., Todaro, M., Watson, R., Yassi, N., Blennow, K., Zetterberg, H., Foster, E., Neal, A., Velakoulis, D., O'Brien, T. J., Eratne, D., & Kwan, P. (2024). Elevated plasma neurofilament light and glial fibrillary acidic protein in epilepsy versus nonepileptic seizures and nonepileptic disorders. Epilepsia. https://doi.org/10.1111/epi.18065

Vancouver

Dobson H, Al Maawali S, Malpas C, Santillo AF, Kang M, Todaro M, et al. Elevated plasma neurofilament light and glial fibrillary acidic protein in epilepsy versus nonepileptic seizures and nonepileptic disorders. Epilepsia. 2024. doi:10.1111/epi.18065

BibTeX
@article{Dobson2024,
  author = {Dobson, Hannah and Al Maawali, Said and Malpas, Charles and Santillo, Alexander F and Kang, Matthew and Todaro, Marian and Watson, Rosie and Yassi, Nawaf and Blennow, Kaj and Zetterberg, Henrik and Foster, Emma and Neal, Andrew and Velakoulis, Dennis and O'Brien, Terence John and Eratne, Dhamidhu and Kwan, Patrick},
  title = {Elevated plasma neurofilament light and glial fibrillary acidic protein in epilepsy versus nonepileptic seizures and nonepileptic disorders},
  journal = {Epilepsia},
  year = {2024},
  doi = {10.1111/epi.18065}
}
Kostenlos starten →